Zobrazeno 1 - 10
of 45
pro vyhledávání: '"M Boscá Watts"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M Chaparro, A Gutiérrez, C Calviño-Suárez, J M Huguet, M Calvo, M Aguas, R Camargo Camero, M Á de Jorge Turrión, D Hervías Cruz, P López Serrano, S Marín Pedrosa, P Martínez Montiel, M Rivero, R Vicente Lidón, L Arias García, M Arroyo, L Bujanda, M J Casanova, M Figueiras, A J Lucendo, N Manceñido Marcos, L Márquez, M D Martín-Arranz, M Boscá Watts, Y Ber, P Ramírez de la Piscina Urraca, I Pérez-Martínez, V Robles, A Ruiz-Cerulla, J M Vázquez Morón, L Madero, M Barreiro-de Acosta, M Capilla, I Vera Mendoza, D Acosta, Y Brenes, S Hermida, P Parra, M G Donday, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 16:i491-i493
Background The safety of ustekinumab in pregnant patients with inflammatory bowel disease (IBD) and in their offspring has been barely studied. Aims Primary: To know the risk of serious adverse events (SAEs) in women exposed to ustekinumab during pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::937c68b486a568e6c69c84324094d726
https://doi.org/10.1093/ecco-jcc/jjab232.672
https://doi.org/10.1093/ecco-jcc/jjab232.672
Autor:
M I Iborra Colomino, A Garrido Marín, B Caballol Oliva, J M Huguet Malavés, L Arias García, F Mesonero Gismero, S J Fernández Prada, M M Boscá Watts, Á Ponferrada Díaz, X Calvet Calvo, A Gutiérrez Casbas, I Ordás Jiménez, L Ruiz Sanchez, B Sicilia Aladren, I Garcia de la Filia, E Domènech Morral, P Nos Mateu
Publikováno v:
Journal of Crohn's and Colitis. 17:i517-i518
Background Recently, a subcutaneous formulation of biosimilar infliximab (CT-P13) (SC-IFX) has been approved for inflammatory bowel disease (IBD). The aims of this study were to evaluate efficacy, safety, pharmacokinetics and patient experience follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c71a5fbe50c93ef27fa5894654b922c0
https://doi.org/10.1093/ecco-jcc/jjac190.0513
https://doi.org/10.1093/ecco-jcc/jjac190.0513
Autor:
C Novella, E Vispo, María García, A Gutiérrez Casbas, I Bastón Rey, C Dueñas Sadornil, J Martínez Cadilla, E Iyo, O. Merino Ochoa, M Cabelo, J González García, C Quílez Ivorra, F Argüelles, Javier P. Gisbert, B David, Jordi Gordillo, Mara Charro, S Rubio Iturria, M. Barreiro-de Acosta, P Ramírez de la Piscina, E. Iglesias Flores, B Velayos Jiménez, E Hinojosa, P Martínez Montiel, M Chaparro, M Boscá-Watts, Francisco Javier Bermejo, José María Huguet, Y. Gonzalez Lama, J M Vázque morón, A I Muñagorri Santos, V M Amo, P Fradejas Salazar, A Núñez Ortiz, M D Martín Arranz, Daniel Ginard, L Ramos, M T Diz-Lois Palomares, E Fernández-Salgado, Maite Arroyo
Publikováno v:
Journal of Crohn's and Colitis. 15:S299-S301
Background Crohn′s disease (CD) is a progressive inflammatory bowel disease that can lead to complications such as strictures or penetrating disease, and ultimately surgery, representing a complex clinical challenge in the care of patients. We aime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b589f9ff13638e95c18df2d589134ba
https://doi.org/10.1093/ecco-jcc/jjab076.389
https://doi.org/10.1093/ecco-jcc/jjab076.389
Autor:
Jordina Llaó, Ana Garre, Olga Merino-Ochoa, Alfredo J. Lucendo, Javier P. Gisbert, David Busquets, M Boscá-Watts, A López Sanromán, C González-Muñoza, Isabel Vera-Mendoza, Agnès Fernández-Clotet, Daniel Ginard, C Rodríguez, J Martínez-Cadilla, Teresa Torrano Martínez, Monica Sierra-Ausin, M Piqueras, Ana Yaiza Carbajo, Saioa Rubio, María José Casanova, E Girona, D Casas-Deza, Carlos Taxonera, M. Chaparro, L Ramos, A. Gutiérrez-Casbas, L Hernández-Villalba, G Suis, E. Domènech, M Calafat, M. Barreiro-de Acosta, Francisco Mesonero, Lucía Márquez, Pilar Nos, M. García, F J Rancel, María Dolores Martín-Arranz, Maite Arroyo, Noemí Manceñido, F Bermejo
Publikováno v:
Journal of Crohn's and Colitis. 14:S026-S028
Background Our aim was to evaluate the effectiveness and safety of tofacitinib in ulcerative colitis (UC) in real life. Methods Patients from the prospectively maintained ENEIDA registry treated with tofacitinib due to active UC were included. Clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::925144b0a67daa968e895a9832ef6da6
https://doi.org/10.1093/ecco-jcc/jjz203.028
https://doi.org/10.1093/ecco-jcc/jjz203.028
Autor:
C Taxonera Samso, M J Fernández-Aceñero, D Olivares, M Calvo, B Casis, F Bermejo, P López Serrano, M Iborra, F Mesonero, M Boscá Watts, C Díaz del Arco, I Vera, S Olivares, C Alba
Publikováno v:
Journal of Crohn's and Colitis. 16:i323-i324
Background The aim of this study was to investigate the association of serum golimumab concentrations (SGC) during maintenance therapy in UC with clinical outcomes including endoscopic and histologic healing. Methods This multicentre, cross-sectional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57059889ac119aa39be949ccec8d8264
https://doi.org/10.1093/ecco-jcc/jjab232.419
https://doi.org/10.1093/ecco-jcc/jjab232.419
Autor:
Xavier Cortés, Alonso Fernández-Nistal, Esther Garcia-Planella, J Santos-Fernández, M. Barreiro-de Acosta, Ignacio Marín-Jiménez, Beatriz Sicilia, Xavier Aldeguer, J. Aparicio, R Ferreiro-Iglesias, Olga Merino, A Forés, Ignacio Tagarro, Carmen Montoto, Federico Argüelles-Arias, Francisco Mesonero, Guillermo Bastida, M Boscá-Watts, Mariam Aguas
Publikováno v:
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 54(1)
Altres ajuts: Takeda Farmacéutica España S.A. Background: Anti-TNFα represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides val
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d944d9fd5e94936abd06793bdc7b7a17
https://pubmed.ncbi.nlm.nih.gov/34244110
https://pubmed.ncbi.nlm.nih.gov/34244110
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
P Ramírez de la Piscina, O. Merino Ochoa, C Quílez Ivorra, E Iyo, Maite Arroyo, Javier P. Gisbert, A Gutiérrez Casbas, David Busquets, C Novella, M. Barreiro-de Acosta, E. Iglesias Flores, Daniel Ginard, B Velayos Jiménez, J M Vázquez Morón, P Fradejas Salazar, A Núñez Ortiz, María García, I Bastón Rey, V M Amo, F Argüelles, M Chaparro, M Boscá-Watts, Francisco Javier Bermejo, Mara Charro, C Dueñas Sadornil, S Rubio Iturria, E Vispo, Jordi Gordillo, M D Martín Arranz, J Martínez Cadilla, A I Muñagorri Santos, J González García, E Hinojosa, P Martínez Montiel, M. E. Cabello, José María Huguet, Y. Gonzalez Lama, M T Diz-Lois Palomares, E Fernández-Salgado, L Ramos
Publikováno v:
Journal of Crohn's and Colitis. 15:S489-S490
Background Whether to use biologic treatment for inflammatory bowel disease as monotherapy or in combination with immunosuppressives has been a matter of debate in the last years. We aimed to evaluate if immunosuppressants influenced the retention ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::347ab24c0a32f1e365bb44bf99d180be
https://doi.org/10.1093/ecco-jcc/jjab076.631
https://doi.org/10.1093/ecco-jcc/jjab076.631
Autor:
M Chaparro, A Garre, M Iborra, M Sierra, M Barreiro-de Acosta, A Fernández-Clotet, L de Castro, M Boscá-Watts, M J Casanova, A López-García, R Lorente, C Rodríguez, A Y Carbajo, M T Arroyo, A Gutiérrez, J Hinojosa, T Martínez-Pérez, A Villoria, F Bermejo, D Busquets, B Camps, F Cañete, N Manceñido, D Monfort, M Navarro-Llavat, J L Pérez-Calle, L Ramos, M Rivero, T Angueira, P Camo, D Carpio, I García-de-la-Filia, C González-Muñoza, L Hernández, J M Huguet, V J Morales, B Sicilia, P Vega, E Domènech, J P Gisbert
Publikováno v:
Journal of Crohn's & Colitis
Background The development program (UNIFI) has shown promising results of ustekinumab in ulcerative colitis (UC) treatment that should be confirmed in clinical practice. Aims Primary: to evaluate the durability of ustekinumab treatment in UC patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b02dbc447088806bfe5ea720e11aa4f8
http://europepmc.org/articles/PMC8194679
http://europepmc.org/articles/PMC8194679